<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002964</url>
  </required_header>
  <id_info>
    <org_study_id>DS 94-10</org_study_id>
    <secondary_id>RPCI-DS-94-10</secondary_id>
    <secondary_id>NCI-V97-1196</secondary_id>
    <nct_id>NCT00002964</nct_id>
  </id_info>
  <brief_title>Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer</brief_title>
  <official_title>Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs that make cancer cells more visible to light may help in the diagnosis of
      head and neck cancer.

      PURPOSE: Phase II trial to study the usefulness of porfimer sodium in diagnosing patients
      with head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether porfimer sodium fluorescence can be used to reveal early
      malignant changes in patients with lesions of the oral cavity. II. Investigate whether
      porfimer sodium fluorescence can define areas of field cancerization in the oral mucosa,
      specifically satellite foci of malignant cells within the margins of an excision. III.
      Determine whether uptake of fluorescence is indicative of disease stage.

      OUTLINE: Patients receive porfimer sodium IV bolus and are kept in subdued light until
      examination with a fluorescence photometer 48 hours later. Patients must avoid sunlight and
      other intense lights for an additional 30 days.

      PROJECTED ACCRUAL: 20 patients will be accrued per year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1995</start_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>porfimer sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluorophotometry</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Malignant or suspected lesions of the head and neck that are
        scheduled for excisional biopsy Lesions no greater than 2 cm in diameter in the mouth,
        oropharynx, hypopharynx or larynx Suspected severe dysplasia, carcinoma in situ and/or
        invasive carcinoma of the head and neck

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life
        expectancy: Not specified Hematopoietic: WBC greater than 3500/mm3 Platelet count greater
        than 100,000/mm3 Hepatic: SGOT and SGPT no greater than 2 times upper limit of normal
        Alkaline phosphatase no greater than 2 times upper limit of normal Bilirubin no greater
        than 2 mg/dL Renal: Creatinine no greater than 2.5 mg/dL Other: No known hypersensitivity
        to porphyrins Not pregnant Fertile patients must use effective birth control

        PRIOR CONCURRENT THERAPY: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wesley L. Hicks, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2004</study_first_posted>
  <last_update_submitted>February 4, 2013</last_update_submitted>
  <last_update_submitted_qc>February 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2013</last_update_posted>
  <keyword>stage 0 oropharyngeal cancer</keyword>
  <keyword>stage 0 laryngeal cancer</keyword>
  <keyword>stage 0 hypopharyngeal cancer</keyword>
  <keyword>stage 0 lip and oral cavity cancer</keyword>
  <keyword>stage I lip and oral cavity cancer</keyword>
  <keyword>stage I hypopharyngeal cancer</keyword>
  <keyword>stage I laryngeal cancer</keyword>
  <keyword>stage I oropharyngeal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
    <mesh_term>Trioxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

